<DOC>
	<DOCNO>NCT01169857</DOCNO>
	<brief_summary>The primary objective test safety efficacy Velcade induce remission WHO class III/IV/V lupus nephritis refractory standard medication .</brief_summary>
	<brief_title>Velcade Proliferative Lupus Nephritis</brief_title>
	<detailed_description>This exploratory single center , open-label , single treatment group assignment , safety , efficacy study enroll 14 patient WHO class III/IV/V lupus nephritis . Subjects receive 12 dos Velcade induce clinical remission .</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Hematuria</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . ACR criterion lupus ( minimum 4 11 ) . 2 . Biopsy proven WHO class III IV V lupus nephritis clinical activity . 3 . GFR must great equal 30 cc/min/1.73 m2 . 4 . Proteinuria must exceed 1000 mg per day except WHO class V lupus nephritis , daily proteinuria must great equal 2000 mg. 5 . Primary therapy active disease must give least 6 month prior protocol enrollment WHO lupus III/IV . 1 . Serum creatinine 3.0 mg/dL repeat test . 2 . Greater 50 % fibrosis renal biopsy . 3 . Platelet count less 30× 109/L . 4 . Absolute neutrophil count le 1.0 × 109/L . 5 . Greater equal Grade 1 peripheral neuropathy . 6 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure . 7 . Hypersensitivity Velcade , boron mannitol . 8 . Serious medical condition infection ( include HIV , HCV , HBV ) psychiatric illness . 9 . Known history untreated positive PPD . 10 . Serious complication systemic lupus cerebral lupus severe active infection . 11 . Diagnosed treat another malignancy within 3 year enrollment . 12 . Greater 1.5x upper limit normal total bilirubin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Proliferative lupus nephritis</keyword>
	<keyword>WHO class III/IV/V lupus nephritis</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Hematuria</keyword>
	<keyword>Velcade</keyword>
	<keyword>SLE</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Proteasome inhibitor</keyword>
</DOC>